drugset / Trial / NCT00370422

Bevacizumab Versus Combined Bevacizumab and Triamcinolone for Refractory Diabetic Macular Edema; a Randomized Clinical Trial

NCT00370422

RandomizedParallel-groupSingle-blindTreatment

Summary

The purpose of this study is to compare the efficacy and safety of intravitreal injection of bevacizumab alone versus bevacizumab combined with triamcinolone for treatment of refractory diabetic macular edema.

Timeline

Start
2005-11
Primary completion
Completion
2006-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Bevacizumab Monoclonal antibody 1.25 mg Intravitreal
Subject Triamcinolone Other / unclassified 2 mg Intravitreal